Biotech | April 29, 2022
Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
The peptide-based vaccine induces a t cell-dependent response
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Sputnik Light is the first component of Sputnik V
Subscribe To Our Newsletter & Stay Updated
